GlobeNewswire

Eurocastle Announces PDMR Dealing and Commencement of the Open Market Buyback Programme

Share

Contact:

Oak Fund Services (Guernsey) Limited

Company Administrator
Attn:  Mark Woodall

Tel:  +44 1481 723450                                                                                   


Eurocastle Announces PDMR Dealing and

Commencement of the Open Market Buyback Programme

­­­Guernsey. 16 September 2019 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces that it in connection with the €60 million tender offer which closed on 10 September 2019, it has been notified that three of the Company’s directors Simon J. Thornton, Jason Sherwill and Randal A. Nardone, participated in the tender offer. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following details of those dealings in its shares by persons discharging managerial responsibilities and their closely associated persons:


Name of the PDMR Financial Instrument Nature of Transaction Date and place of transaction Volume and price of transaction
Mr. Randal A. Nardone Ordinary Shares Disposal of shares as a result of participating in the €60m Eurocastle Share Tender Offer. 10 September 2019, Euronext, Amsterdam 173,671 shares at €8.45 per share

 
Dr. Simon John Thornton Ordinary Shares Disposal of shares as a result of participating in the €60m Eurocastle Share Tender Offer. 10 September 2019, Euronext, Amsterdam 2,120 shares at €8.45 per share

 
Mr. Jason de Beauvoir Sherwill (via Forein Limited, Closely Associated Person) Ordinary Shares Disposal of shares as a result of participating in the €60m Eurocastle Share Tender Offer. 10 September 2019, Euronext, Amsterdam 2,435 shares at €8.45 per share

 


As a consequence of the above, after taking into account the anticipated cancellation of ordinary shares following the settlement of the tender offer later today (as previously announced on 11 September 2019):


  • The total number of Ordinary Shares of the Company in issue will be 55,379,438;
  • The total number of Ordinary Shares held by Eurocastle in treasury will be 18,851,407 (34.04% of the Ordinary Shares in issue); and
  • The total number of voting rights exercisable by holders of Ordinary Shares of the Company will be 36,528,031, as voting rights of shares held in treasury are suspended


In addition, the Share Buy-Back Programme announced on 9 August 2019 has commenced today and will continue up until the earlier of 13 November 2019 and the date on which €2 million of ordinary shares have been acquired under the programme.
  
    

Eurocastle Investment Limited is a publicly traded closed-ended investment company that focuses on investing in performing and non-performing loans and other real estate related assets primarily in Italy. The Company is Euro denominated and is listed on Euronext Amsterdam under the symbol “ECT”. Eurocastle is managed by an affiliate of Fortress Investment Group LLC, a leading global investment manager. For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

New Group Chief Financial Officer13.12.2019 15:20:00 CETPress release

COMPANY ANNOUNCEMENT NO. 15-2019, DECEMBER 13, 2019, COPENHAGEN Roland M. Andersen is appointed Chief Financial Officer and member of Group Executive Management. In continuation of company announcement no. 14, we are pleased to announce the appointment of our new Chief Financial Officer and member of Group Executive Management. Roland M. Andersen joins FLSmidth from NKT and brings 25 years of solid experience and new competences through his time as CFO with public as well as private equity owned companies which will help strengthen FLSmidth. Roland is a strong financial executive with demonstrated success from his prior CFO roles at A.P. Moller Maersk, Telenor/Cybercity, Torm and most recently NKT where he played a key role in leading the company through strategic transformation and further acted as CEO for a period of time. Roland also brings international experience to FLSmidth having lived and worked abroad in Asia and other parts of the world. “We are excited that Roland has decide

Nokia signs contract with TIM Brazil to launch IoT offer13.12.2019 14:00:00 CETPress release

Press Release Nokia signs contract with TIM Brazil to launch IoT offer Nokia’s first Worldwide IoT Network Grid (WING) deal in Latin America, enabling TIM to expand IoT services in Brazil TIM’s enterprise customers will be able to offer IoT services across various industries faster by using the fully virtualized WING infrastructure, offered as a managed service Widespread adoption of IoT technologies estimated to add USD 200 billion to Brazilian economy by 2025* 12 December 2019 Espoo, Finland – Nokia has signed a contract with telecommunications giant TIM to provide Internet of Things (IoT) services to its enterprise customers in Brazil. Using the fully virtualized Nokia Worldwide IoT Network Grid (WING) managed service offer, TIM and its enterprise customers across industries,such as automotive and agriculture, will be able to capture IoT opportunities faster and more securely. The Brazilian market is the largest IoT market in Latin America, with widespread adoption of IoT technologi

Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD13.12.2019 13:03:00 CETPress release

In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal fluid and/or sub-retinal fluid at week 16 and year one with Beovu1 In a key pre-specified secondary endpoint, over half of Beovu 6mg patients (56% in HAWK and 51% in HARRIER) were maintained on three-month dosing intervals immediately after the loading phase through year one1 Frequent injections are a common reason patients drop off treatment for wet AMD, a leading cause of blindness that affects more than 20M people worldwide2-4 Basel, December 13, 2019 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu® (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD). “Today’s CHMP opinion brings us ano

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business13.12.2019 13:00:00 CETPress release

OUTOTEC OYJ STOCK EXCHANGE RELEASE December 13, 2019 at 2:00 PM The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business The Finnish Financial Supervisory Authority has today on December 13, 2019, approved a supplement to the Finnish language demerger prospectus (the “Prospectus”) relating to the combination of Outotec Oyj (“Outotec”) and Metso Corporation’s (“Metso”) Minerals business (the “Metso Minerals Business”). The supplement relates to the stock exchange release published by Outotec on December 10, 2019, according to which Outotec has taken a strategic decision to divest three businesses in the Metals, Energy & Water segment, which are the aluminum business, waste-to-energy solutions and sludge incineration. The supplement also relates to the stock exchange release published by Outotec on the same day, according to which Outotec lowers its sales guidance for 2019 due to the in

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business13.12.2019 13:00:00 CETPress release

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals Business Metso Corporation, Stock exchange release on December 13, 2019, at 2:00 p.m. EET The Finnish Financial Supervisory Authority has today on December 13, 2019, approved a supplement to the Finnish language demerger prospectus (the “Prospectus”) relating to the combination of Outotec Oyj (“Outotec”) and Metso Corporation’s (“Metso”) Minerals business (the “Metso Minerals Business”). The supplement relates to the stock exchange release published by Outotec on December 10, 2019, according to which Outotec has taken a strategic decision to divest three businesses in the Metals, Energy & Water segment, which are the aluminum business, waste-to-energy solutions and sludge incineration. The supplement also relates to the stock exchange release published by Outotec on the same day, according to which Outotec lowers its sales guidance for 2

Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline13.12.2019 10:26:00 CETPress release

COPENHAGEN, Denmark, December 13, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has received antitrust clearance in the U.S., Spain and Portugal of its planned acquisition of the two commercial vaccines, Rabipur®/RabAvert® and Encepur®, from GlaxoSmithKline plc (GSK), announced on October 21, 2019. With these clearances, and the recent approval from the Company’s shareholders of a rights issue to fund part of the acquisition, the transaction will now proceed towards closing, expected by December 31, 2019. For more information about the transaction, see company announcement no. 19/2019. About Bavarian Nordic Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to unlock the power of the immune system to improve p